Andrea van Elsas has joined the supervisory board of Netherlands-based InteRNA Technologies BV which is developing microRNA therapeutics for cancer. Dr van Elsas is a venture partner with Third Rock Ventures of Boston, US. He was previously chief scientific officer at Aduro Biotech, an immunotherapy company. Before this, he worked at the Dutch company, Organon, which was acquired by Schering-Plough and later by Merck & Co Inc. At Merck, Dr van Elsas led the checkpoint inhibitor programme which resulted in the development of pembrolizumab (Keytruda) for cancer.
InteRNA announced the appointment on 12 October 2021.
Copyright 2021 Evernow Publishing Ltd